Exchange: NASDAQ
Symbol: VTVT
President & CEO: Stephen L. Holcombe
HQ: High Point, NC
Website: www.vtvtherapeutics.com
vTv Therapeutics LLC is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and type 2 diabetes, as well as a wide range of other diseases including central nervous system and metabolic disorders, inflammation and cancer. The company’s Phase 3 investigational therapy, azeliragon, targets a receptor in the brain, called RAGE, which is believed to play a fundamental role in Alzheimer’s disease. Scientists believe that blocking RAGE in the brain may slow the progression of clinical symptoms of the disease. There is currently no other company with a clinical stage RAGE program in Alzheimer’s disease. Additionally, vTv announced positive Phase 2 results last year for both of its lead diabetes compounds, TTP273 and TTP399, each of which demonstrated statistically significant reductions in HbA1c.